Trump drug pricing model may impact four companies
A finalized Trump administration rule to cut hospital drug prices for Medicare patients may apply to just four drugmakers after exempting companies with separate deals. HHS also reduced projected savings for the program down to $440 million.
Xurve View
Insights:
Xurve View
A new United States Medicare drug pricing model could apply to just four manufacturers after sweeping exemptions for companies with separate White House agreements. The policy shift slashes projected government savings by more than 96%. The narrowing scope limits the program's immediate impact on hospital drug expenditures.
